Hospital Acquired Disease Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Hospital Acquired Disease Testing Market is projected to experience significant growth, expanding from USD 5.29 Billion in 2025 to USD 8.34 Billion by 2031, reflecting a CAGR of 7.88%. This market encompasses various screening procedures and diagnostic assays intended to detect infectious agents, including viruses and bacteria, that are transmitted to patients within medical environments. Key drivers accelerating this growth include the increasing incidence of nosocomial infections and a growing geriatric demographic that is highly vulnerable to such conditions, alongside strict government mandates for infection control and the essential adoption of antimicrobial stewardship programs.

Despite these growth factors, the market faces a substantial obstacle in the form of high costs linked to advanced molecular diagnostics, which restricts their deployment in regions with limited resources. Nevertheless, the demand for these testing solutions remains acute given the heavy burden of resistant pathogens. Data from the World Health Organization underscores this urgency, estimating that in 2024, approximately 136 million antibiotic-resistant healthcare-associated infections occurred globally, highlighting the critical need for effective diagnostic interventions.

Market Drivers

Advancements in rapid diagnostic technologies are fundamentally transforming the Global Hospital Acquired Disease Testing Market by facilitating earlier and more precise pathogen detection. The shift from conventional culture-based techniques to sophisticated molecular diagnostics, particularly syndromic testing, enables medical professionals to identify multiple infectious agents in hours instead of days, which is crucial for timely antimicrobial therapy and improved patient outcomes. The commercial viability of these innovations is evident in their increasing adoption; for example, bioMérieux reported in their 'First-Half 2024 Financial Results' in September 2024 that organic sales of their BIOFIRE non-respiratory panels, essential for diagnosing conditions like meningitis and sepsis, rose by 19%.

At the same time, the escalating threat of multidrug-resistant pathogens is driving the necessity for these advanced testing solutions as healthcare facilities fight to control superbugs. As resistance mechanisms evolve and standard antibiotics become less effective, precise diagnostics are essential for guiding antimicrobial stewardship and preventing outbreaks. This urgency is emphasized by long-term forecasts; a September 2024 report by Wellcome predicts over 39 million deaths will be attributed to antibiotic-resistant infections between 2025 and 2050, while the Centers for Disease Control and Prevention noted in July 2024 that reported clinical cases of the multidrug-resistant fungus Candida auris increased nearly five-fold since 2019.

Market Challenges

The substantial expense associated with advanced molecular diagnostics poses a significant barrier to the growth of the Global Hospital Acquired Disease Testing Market. Healthcare institutions, particularly those in resource-limited settings, often face difficult decisions when balancing the acquisition of cutting-edge screening tools against essential operational costs. Consequently, the adoption of precise yet costly molecular assays is often limited, compelling many providers to depend on traditional, less expensive diagnostic methods that may delay necessary treatment and infection control protocols.

This financial constraint is further illustrated by the relatively low investment in diagnostic technologies compared to overall healthcare spending. Market expansion is stifled when budgetary allocations for testing remain disproportionately small relative to other medical verticals. According to MedTech Europe, expenditure on in vitro diagnostics in 2024 was estimated to account for only 0.6% of total healthcare spending. This statistic underscores the severe budgetary limitations that hinder the uptake of advanced testing solutions, preventing the market from fully addressing the demand generated by the prevalence of infectious diseases.

Market Trends

The expansion of Point-of-Care (POC) testing is decentralizing the detection of hospital-acquired diseases, enabling healthcare providers to identify pathogens directly at the bedside rather than waiting for central laboratory results. This transition significantly lowers turnaround times, allowing for immediate isolation and treatment decisions that are vital for containing outbreaks in sensitive wards. The market impact of this trend is highlighted by the swift commercial adoption of decentralized molecular platforms; for instance, bioMérieux reported in March 2025 that sales of its SPOTFIRE point-of-care solution reached €95 million for the year, driven by a growing installed base across medical facilities.

Concurrently, there is a notable shift toward real-time digital surveillance systems designed to monitor infection rates and antimicrobial resistance patterns throughout healthcare networks. These systems compile data from inpatient stays and surgical procedures to pinpoint high-risk areas and ensure compliance with infection control standards, creating a continuous feedback loop for administrators. Participation in these monitoring programs is fueling demand for consistent testing, as evidenced by the UK Health Security Agency's December 2025 report, which noted a 7.9% increase in the volume of surgical procedures submitted for surveillance analysis compared to the previous year, reflecting increased adherence to monitoring mandates.

Key Players Profiled in the Hospital Acquired Disease Testing Market

• bioMerieux SA
• Abbott Laboratories Inc.
• F. Hoffmann-La Roche Ltd.
• Siemens Healthcare Private Limited
• Becton, Dickinson and Company
• Bioscience, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• Hologic, Inc.
• Meridian Bioscience, Inc.

Report Scope

In this report, the Global Hospital Acquired Disease Testing Market has been segmented into the following categories:

Hospital Acquired Disease Testing Market, by Test Type:

• Molecular
• Conventional

Hospital Acquired Disease Testing Market, by Infection Type:

• UTI
• Pneumonia
• Surgical Site Infection
• Blood Stream Infections
• Others

Hospital Acquired Disease Testing Market, by Product:

• Consumables
• Instruments

Hospital Acquired Disease Testing Market, by Type:

• Blood Tests
• Urinalysis

Hospital Acquired Disease Testing Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hospital Acquired Disease Testing Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.